VisionGate
VisionGate is a biotechnology company focused on early lung cancer detection through non-intrusive testing and advanced imaging technologies. Their flagship product, the LuCED Lung Test, utilizes patented Cell-CT imaging and AI-powered detection to identify abnormal cells in sputum samples, providing high accuracy in early-stage lung cancer diagnosis. With a strong intellectual property portfolio of 35 patents and ongoing clinical partnerships, VisionGate is positioned to make significant advancements in cancer diagnostics and improve patient outcomes.
VisionGate
VisionGate is a biotechnology company focused on early lung cancer detection through non-intrusive testing and advanced imaging technologies. Their flagship product, the LuCED Lung Test, utilizes patented Cell-CT imaging and AI-powered detection to identify abnormal cells in sputum samples, providing high accuracy in early-stage lung cancer diagnosis. With a strong intellectual property portfolio of 35 patents and ongoing clinical partnerships, VisionGate is positioned to make significant advancements in cancer diagnostics and improve patient outcomes.